APO Research
Talk to an analyst

APO RESEARCH · REPORT

Blood Product

Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called blood product.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called blood product.

Selected research

Market Analysis & Forecast

Global Blood Product Market Analysis and Forecast 2026-2032

1 January 2026207 pages

Choose your research edition.

Industry ResearchBlood Product Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Blood Product Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Blood Product Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Blood Product Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Blood Product Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called blood product.

The major players in global blood product market include Takeda, CSL, etc. The top 3 players occupy about 60% shares of the global market. North America and Europe are main markets, they occupy about 65% of the global market.

Report Includes

Read the full market overview

This report presents an overview of global market for Blood Product, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Blood Product, also provides the revenue of main regions and countries. Of the upcoming market potential for Blood Product, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Blood Product revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Blood Product market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Blood Product revenue, projected growth trends, production technology, application and end-user industry.

Blood Product Segment by Company

Takeda

CSL

Grifols

Octapharma

Kedrion

LFB Group

Biotest

BPL

Shanghai RAAS

China Biologic Products

Hualan Biological Engineering Inc.

Beijing Tiantan Biological Products Corp

Pacific Shuanglin

Boya Bio-Pharmaceutical

Paisi Feike Biology Pharmacy Co., Ltd.

Xinjiang Deyuan Bioengineering

Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

Shenzhen Weiguang

Shanxi Kangbao

Nanyue Biopharming Corporation Ltd

Blood Product Segment by Type

Albumin

Immunoglobulin

Clotting Factor

Others

Blood Product Segment by Application

Bleeding Wound

Immunodeficiency

HBV

Tetanus

Rabies

Hemophilia

Others

Blood Product Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Blood Product market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Blood Product and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Blood Product.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Blood Product in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Blood Product company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Blood Product revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Blood Product Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Albumin Major Player Table 3. Immunoglobulin Major Player Table 4. Clotting Factor Major Player Table 5. Others Major Player Table 6. Global Blood Product Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Bleeding Wound Major Player Table 8. Immunodeficiency Major Player Table 9. HBV Major Player Table 10. Tetanus Major Player Table 11. Rabies Major Player Table 12. Hemophilia Major Player Table 13. Others Major Player Table 14. Blood Product Industry Trends Table 15. Blood Product Industry Drivers Table 16. Blood Product Industry Opportunities and Challenges Table 17. Blood Product Industry Restraints Table 18. Global Blood Product Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 19. Global Blood Product Market Size by Region (2021-2026) & (US$ Million) Table 20. Global Blood Product Market Share by Region (2021-2026) Table 21. Global Blood Product Market Size by Region (2027-2032) & (US$ Million) Table 22. Global Blood Product Market Share by Region (2027-2032) Table 23. Global Blood Product Revenue by Players (US$ Million) & (2021-2026) Table 24. Global Blood Product Revenue Market Share by Players (2021-2026) Table 25. Global Blood Product Key Players Ranking, 2024 VS 2025 VS 2026 Table 26. Global Blood Product Key Players Headquarters & Area Served Table 27. Global Blood Product Players, Product Type & Application Table 28. Global Blood Product Players Establishment Date Table 29. Global Players Market Concentration Ratio (CR5 and HHI) Table 30. Global Blood Product by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 31. Global Blood Product Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Blood Product Revenue by Type (2021-2026) & (US$ Million) Table 33. Global Blood Product Revenue by Type (2027-2032) & (US$ Million) Table 34. Global Blood Product Revenue Market Share by Type (2021-2026) Table 35. Global Blood Product Revenue Market Share by Type (2027-2032) Table 36. Global Blood Product Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Blood Product Revenue by Application (2021-2026) & (US$ Million) Table 38. Global Blood Product Revenue by Application (2027-2032) & (US$ Million) Table 39. Global Blood Product Revenue Market Share by Application (2021-2026) Table 40. Global Blood Product Revenue Market Share by Application (2027-2032) Table 41. Takeda Company Information Table 42. Takeda Business Overview Table 43. Takeda Blood Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Takeda Blood Product Product Portfolio Table 45. Takeda Recent Development Table 46. CSL Company Information Table 47. CSL Business Overview Table 48. CSL Blood Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. CSL Blood Product Product Portfolio Table 50. CSL Recent Development Table 51. Grifols Company Information Table 52. Grifols Business Overview Table 53. Grifols Blood Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Grifols Blood Product Product Portfolio Table 55. Grifols Recent Development Table 56. Octapharma Company Information Table 57. Octapharma Business Overview Table 58. Octapharma Blood Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Octapharma Blood Product Product Portfolio Table 60. Octapharma Recent Development Table 61. Kedrion Company Information Table 62. Kedrion Business Overview Table 63. Kedrion Blood Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Kedrion Blood Product Product Portfolio Table 65. Kedrion Recent Development Table 66. LFB Group Company Information Table 67. LFB Group Business Overview Table 68. LFB Group Blood Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. LFB Group Blood Product Product Portfolio Table 70. LFB Group Recent Development Table 71. Biotest Company Information Table 72. Biotest Business Overview Table 73. Biotest Blood Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Biotest Blood Product Product Portfolio Table 75. Biotest Recent Development Table 76. BPL Company Information Table 77. BPL Business Overview Table 78. BPL Blood Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. BPL Blood Product Product Portfolio Table 80. BPL Recent Development Table 81. Shanghai RAAS Company Information Table 82. Shanghai RAAS Business Overview Table 83. Shanghai RAAS Blood Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Shanghai RAAS Blood Product Product Portfolio Table 85. Shanghai RAAS Recent Development Table 86. China Biologic Products Company Information Table 87. China Biologic Products Business Overview Table 88. China Biologic Products Blood Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. China Biologic Products Blood Product Product Portfolio Table 90. China Biologic Products Recent Development Table 91. Hualan Biological Engineering Inc. Company Information Table 92. Hualan Biological Engineering Inc. Business Overview Table 93. Hualan Biological Engineering Inc. Blood Product Sales (K Bottles), Revenue (US$ Million), Price (US$/Bottle) and Gross Margin (2021-2026) Table 94. Hualan Biological Engineering Inc. Blood Product Product Portfolio Table 95. Hualan Biological Engineering Inc. Recent Development Table 96. Beijing Tiantan Biological Products Corp Company Information Table 97. Beijing Tiantan Biological Products Corp Business Overview Table 98. Beijing Tiantan Biological Products Corp Blood Product Sales (K Bottles), Revenue (US$ Million), Price (US$/Bottle) and Gross Margin (2021-2026) Table 99. Beijing Tiantan Biological Products Corp Blood Product Product Portfolio Table 100. Beijing Tiantan Biological Products Corp Recent Development Table 101. Pacific Shuanglin Company Information Table 102. Pacific Shuanglin Business Overview Table 103. Pacific Shuanglin Blood Product Sales (K Bottles), Revenue (US$ Million), Price (US$/Bottle) and Gross Margin (2021-2026) Table 104. Pacific Shuanglin Blood Product Product Portfolio Table 105. Pacific Shuanglin Recent Development Table 106. Boya Bio-Pharmaceutical Company Information Table 107. Boya Bio-Pharmaceutical Business Overview Table 108. Boya Bio-Pharmaceutical Blood Product Sales (K Bottles), Revenue (US$ Million), Price (US$/Bottle) and Gross Margin (2021-2026) Table 109. Boya Bio-Pharmaceutical Blood Product Product Portfolio Table 110. Boya Bio-Pharmaceutical Recent Development Table 111. Paisi Feike Biology Pharmacy Co., Ltd. Company Information Table 112. Paisi Feike Biology Pharmacy Co., Ltd. Business Overview Table 113. Paisi Feike Biology Pharmacy Co., Ltd. Blood Product Sales (K Bottles), Revenue (US$ Million), Price (US$/Bottle) and Gross Margin (2021-2026) Table 114. Paisi Feike Biology Pharmacy Co., Ltd. Blood Product Product Portfolio Table 115. Paisi Feike Biology Pharmacy Co., Ltd. Recent Development Table 116. Xinjiang Deyuan Bioengineering Company Information Table 117. Xinjiang Deyuan Bioengineering Business Overview Table 118. Xinjiang Deyuan Bioengineering Blood Product Sales (K Bottles), Revenue (US$ Million), Price (US$/Bottle) and Gross Margin (2021-2026) Table 119. Xinjiang Deyuan Bioengineering Blood Product Product Portfolio Table 120. Xinjiang Deyuan Bioengineering Recent Development Table 121. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Company Information Table 122. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Business Overview Table 123. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Blood Product Sales (K Bottles), Revenue (US$ Million), Price (US$/Bottle) and Gross Margin (2021-2026) Table 124. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Blood Product Product Portfolio Table 125. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Recent Development Table 126. Shenzhen Weiguang Company Information Table 127. Shenzhen Weiguang Business Overview Table 128. Shenzhen Weiguang Blood Product Sales (K Bottles), Revenue (US$ Million), Price (US$/Bottle) and Gross Margin (2021-2026) Table 129. Shenzhen Weiguang Blood Product Product Portfolio Table 130. Shenzhen Weiguang Recent Development Table 131. Shanxi Kangbao Company Information Table 132. Shanxi Kangbao Business Overview Table 133. Shanxi Kangbao Blood Product Sales (K Bottles), Revenue (US$ Million), Price (US$/Bottle) and Gross Margin (2021-2026) Table 134. Shanxi Kangbao Blood Product Product Portfolio Table 135. Shanxi Kangbao Recent Development Table 136. Nanyue Biopharming Corporation Ltd Company Information Table 137. Nanyue Biopharming Corporation Ltd Business Overview Table 138. Nanyue Biopharming Corporation Ltd Blood Product Sales (K Bottles), Revenue (US$ Million), Price (US$/Bottle) and Gross Margin (2021-2026) Table 139. Nanyue Biopharming Corporation Ltd Blood Product Product Portfolio Table 140. Nanyue Biopharming Corporation Ltd Recent Development Table 141. North America Blood Product Revenue by Type (2021-2026) & (US$ Million) Table 142. North America Blood Product Revenue by Type (2027-2032) & (US$ Million) Table 143. North America Blood Product Revenue by Application (2021-2026) & (US$ Million) Table 144. North America Blood Product Revenue by Application (2027-2032) & (US$ Million) Table 145. North America Blood Product Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 146. North America Blood Product Revenue by Country (2021-2026) & (US$ Million) Table 147. North America Blood Product Revenue by Country (US$ Million) & (2027-2032) Table 148. Europe Blood Product Revenue by Type (2021-2026) & (US$ Million) Table 149. Europe Blood Product Revenue by Type (2027-2032) & (US$ Million) Table 150. Europe Blood Product Revenue by Application (2021-2026) & (US$ Million) Table 151. Europe Blood Product Revenue by Application (2027-2032) & (US$ Million) Table 152. Europe Blood Product Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 153. Europe Blood Product Revenue by Country (2021-2026) & (US$ Million) Table 154. Europe Blood Product Revenue by Country (US$ Million) & (2027-2032) Table 155. China Blood Product Revenue by Type (2021-2026) & (US$ Million) Table 156. China Blood Product Revenue by Type (2027-2032) & (US$ Million) Table 157. China Blood Product Revenue by Application (2021-2026) & (US$ Million) Table 158. China Blood Product Revenue by Application (2027-2032) & (US$ Million) Table 159. Asia Blood Product Revenue by Type (2021-2026) & (US$ Million) Table 160. Asia Blood Product Revenue by Type (2027-2032) & (US$ Million) Table 161. Asia Blood Product Revenue by Application (2021-2026) & (US$ Million) Table 162. Asia Blood Product Revenue by Application (2027-2032) & (US$ Million) Table 163. Asia Blood Product Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 164. Asia Blood Product Revenue by Region (US$ Million) & (2021-2026) Table 165. Asia Blood Product Revenue by Region (US$ Million) & (2027-2032) Table 166. SAMEA Blood Product Revenue by Type (2021-2026) & (US$ Million) Table 167. SAMEA Blood Product Revenue by Type (2027-2032) & (US$ Million) Table 168. SAMEA Blood Product Revenue by Application (2021-2026) & (US$ Million) Table 169. SAMEA Blood Product Revenue by Application (2027-2032) & (US$ Million) Table 170. SAMEA Blood Product Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 171. SAMEA Blood Product Revenue by Country (2021-2026) & (US$ Million) Table 172. SAMEA Blood Product Revenue by Country (US$ Million) & (2027-2032) Table 173. Research Programs/Design for This Report Table 174. Authors List of This Report Table 175. Secondary Sources Table 176. Primary Sources List of Figures Figure 1. Blood Product Image Figure 2. Global Blood Product Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Blood Product Market Size Share 2021 VS 2025 VS 2032 Figure 4. Albumin Image Figure 5. Immunoglobulin Image Figure 6. Clotting Factor Image Figure 7. Others Image Figure 8. Global Blood Product Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Blood Product Market Size Share 2021 VS 2025 VS 2032 Figure 10. Bleeding Wound Image Figure 11. Immunodeficiency Image Figure 12. HBV Image Figure 13. Tetanus Image Figure 14. Rabies Image Figure 15. Hemophilia Image Figure 16. Others Image Figure 17. Global Blood Product Market Size (US$ Million) & (2021-2032) Figure 18. Global Blood Product Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 19. Global Blood Product Market Share by Region: 2021 VS 2025 VS 2032 Figure 20. Global Blood Product Players Revenue Share Top 10 and Top 5 in 2025 Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Blood Product Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Blood Product Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Blood Product Revenue Market Share by Type (2021-2032) Figure 25. Global Blood Product Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Blood Product Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 27. Global Blood Product Revenue Market Share by Application (2021-2032) Figure 28. North America Blood Product Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. North America Blood Product Revenue Share by Type (2021-2032) Figure 30. North America Blood Product Revenue Share by Application (2021-2032) Figure 31. North America Blood Product Revenue Share by Country (2021-2032) Figure 32. United States Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Canada Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Mexico Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Europe Blood Product Revenue YoY Growth (2021-2032) & (US$ Million) Figure 36. Europe Blood Product Revenue Share by Type (2021-2032) Figure 37. Europe Blood Product Revenue Share by Application (2021-2032) Figure 38. Europe Blood Product Revenue Share by Country (2021-2032) Figure 39. Germany Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. France Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. U.K. Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Italy Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Spain Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Russia Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Netherlands Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. Nordic Countries Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 47. China Blood Product Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. China Blood Product Revenue Share by Type (2021-2032) Figure 49. China Blood Product Revenue Share by Application (2021-2032) Figure 50. Asia Blood Product Revenue YoY Growth (2021-2032) & (US$ Million) Figure 51. Asia Blood Product Revenue Share by Type (2021-2032) Figure 52. Asia Blood Product Revenue Share by Application (2021-2032) Figure 53. Asia Blood Product Revenue Share by Region (2021-2032) Figure 54. Japan Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. South Korea Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. India Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Australia Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Taiwan Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Southeast Asia Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. SAMEA Blood Product Revenue YoY Growth (2021-2032) & (US$ Million) Figure 61. SAMEA Blood Product Revenue Share by Type (2021-2032) Figure 62. SAMEA Blood Product Revenue Share by Application (2021-2032) Figure 63. SAMEA Blood Product Revenue Share by Country (2021-2032) Figure 64. Brazil Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Argentina Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Chile Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Colombia Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Peru Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Saudi Arabia Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Israel Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. UAE Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Turkey Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Iran Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Egypt Blood Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Albumin
  • Immunoglobulin
  • Clotting Factor
  • Others
Applications
  • Bleeding Wound
  • Immunodeficiency
  • HBV
  • Tetanus
  • Rabies
  • Hemophilia
  • Others
Companies covered
  • Takeda
  • CSL
  • Grifols
  • Octapharma
  • Kedrion
  • LFB Group
  • Biotest
  • BPL
  • Shanghai RAAS
  • China Biologic Products
  • Hualan Biological Engineering Inc.
  • Beijing Tiantan Biological Products Corp
  • Pacific Shuanglin
  • Boya Bio-Pharmaceutical
  • Paisi Feike Biology Pharmacy Co., Ltd.
  • Xinjiang Deyuan Bioengineering
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • Shenzhen Weiguang
  • Shanxi Kangbao
  • Nanyue Biopharming Corporation Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Blood Product Market by Type
  3. 1.2.1 Global Blood Product Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Albumin
  5. 1.2.3 Immunoglobulin
  6. 1.2.4 Clotting Factor
  7. 1.2.5 Others
  8. 1.3 Blood Product Market by Application
  9. 1.3.1 Global Blood Product Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Bleeding Wound
  11. 1.3.3 Immunodeficiency
  12. 1.3.4 HBV
  13. 1.3.5 Tetanus
  14. 1.3.6 Rabies
  15. 1.3.7 Hemophilia
  16. 1.3.8 Others
  17. 1.4 Assumptions and Limitations
  18. 1.5 Study Goals and Objectives
2 Blood Product Market Dynamics
  1. 2.1 Blood Product Industry Trends
  2. 2.2 Blood Product Industry Drivers
  3. 2.3 Blood Product Industry Opportunities and Challenges
  4. 2.4 Blood Product Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Blood Product Market Perspective (2021-2032)
  2. 3.2 Global Blood Product Growth Trends by Region
  3. 3.2.1 Global Blood Product Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Blood Product Market Size by Region (2021-2026)
  5. 3.2.3 Global Blood Product Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Blood Product Revenue by Players
  2. 4.1.1 Global Blood Product Revenue by Players (2021-2026)
  3. 4.1.2 Global Blood Product Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Blood Product Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Blood Product Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Blood Product Key Players Headquarters & Area Served
  7. 4.4 Global Blood Product Players, Product Type & Application
  8. 4.5 Global Blood Product Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Blood Product Market CR5 and HHI
  11. 4.6.3 2025 Blood Product Tier 1, Tier 2, and Tier 3
5 Blood Product Market Size by Type
  1. 5.1 Global Blood Product Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Blood Product Revenue by Type (2021-2032)
  3. 5.3 Global Blood Product Revenue Market Share by Type (2021-2032)
6 Blood Product Market Size by Application
  1. 6.1 Global Blood Product Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Blood Product Revenue by Application (2021-2032)
  3. 6.3 Global Blood Product Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda
  2. 7.1.1 Takeda Company Information
  3. 7.1.2 Takeda Business Overview
  4. 7.1.3 Takeda Blood Product Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Blood Product Product Portfolio
  6. 7.1.5 Takeda Recent Developments
  7. 7.2 CSL
  8. 7.2.1 CSL Company Information
  9. 7.2.2 CSL Business Overview
  10. 7.2.3 CSL Blood Product Revenue and Gross Margin (2021-2026)
  11. 7.2.4 CSL Blood Product Product Portfolio
  12. 7.2.5 CSL Recent Developments
  13. 7.3 Grifols
  14. 7.3.1 Grifols Company Information
  15. 7.3.2 Grifols Business Overview
  16. 7.3.3 Grifols Blood Product Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Grifols Blood Product Product Portfolio
  18. 7.3.5 Grifols Recent Developments
  19. 7.4 Octapharma
  20. 7.4.1 Octapharma Company Information
  21. 7.4.2 Octapharma Business Overview
  22. 7.4.3 Octapharma Blood Product Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Octapharma Blood Product Product Portfolio
  24. 7.4.5 Octapharma Recent Developments
  25. 7.5 Kedrion
  26. 7.5.1 Kedrion Company Information
  27. 7.5.2 Kedrion Business Overview
  28. 7.5.3 Kedrion Blood Product Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Kedrion Blood Product Product Portfolio
  30. 7.5.5 Kedrion Recent Developments
  31. 7.6 LFB Group
  32. 7.6.1 LFB Group Company Information
  33. 7.6.2 LFB Group Business Overview
  34. 7.6.3 LFB Group Blood Product Revenue and Gross Margin (2021-2026)
  35. 7.6.4 LFB Group Blood Product Product Portfolio
  36. 7.6.5 LFB Group Recent Developments
  37. 7.7 Biotest
  38. 7.7.1 Biotest Company Information
  39. 7.7.2 Biotest Business Overview
  40. 7.7.3 Biotest Blood Product Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Biotest Blood Product Product Portfolio
  42. 7.7.5 Biotest Recent Developments
  43. 7.8 BPL
  44. 7.8.1 BPL Company Information
  45. 7.8.2 BPL Business Overview
  46. 7.8.3 BPL Blood Product Revenue and Gross Margin (2021-2026)
  47. 7.8.4 BPL Blood Product Product Portfolio
  48. 7.8.5 BPL Recent Developments
  49. 7.9 Shanghai RAAS
  50. 7.9.1 Shanghai RAAS Company Information
  51. 7.9.2 Shanghai RAAS Business Overview
  52. 7.9.3 Shanghai RAAS Blood Product Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Shanghai RAAS Blood Product Product Portfolio
  54. 7.9.5 Shanghai RAAS Recent Developments
  55. 7.10 China Biologic Products
  56. 7.10.1 China Biologic Products Company Information
  57. 7.10.2 China Biologic Products Business Overview
  58. 7.10.3 China Biologic Products Blood Product Revenue and Gross Margin (2021-2026)
  59. 7.10.4 China Biologic Products Blood Product Product Portfolio
  60. 7.10.5 China Biologic Products Recent Developments
  61. 7.11 Hualan Biological Engineering Inc.
  62. 7.11.1 Hualan Biological Engineering Inc. Company Information
  63. 7.11.2 Hualan Biological Engineering Inc. Business Overview
  64. 7.11.3 Hualan Biological Engineering Inc. Blood Product Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Hualan Biological Engineering Inc. Blood Product Product Portfolio
  66. 7.11.5 Hualan Biological Engineering Inc. Recent Developments
  67. 7.12 Beijing Tiantan Biological Products Corp
  68. 7.12.1 Beijing Tiantan Biological Products Corp Company Information
  69. 7.12.2 Beijing Tiantan Biological Products Corp Business Overview
  70. 7.12.3 Beijing Tiantan Biological Products Corp Blood Product Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Beijing Tiantan Biological Products Corp Blood Product Product Portfolio
  72. 7.12.5 Beijing Tiantan Biological Products Corp Recent Developments
  73. 7.13 Pacific Shuanglin
  74. 7.13.1 Pacific Shuanglin Company Information
  75. 7.13.2 Pacific Shuanglin Business Overview
  76. 7.13.3 Pacific Shuanglin Blood Product Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Pacific Shuanglin Blood Product Product Portfolio
  78. 7.13.5 Pacific Shuanglin Recent Developments
  79. 7.14 Boya Bio-Pharmaceutical
  80. 7.14.1 Boya Bio-Pharmaceutical Company Information
  81. 7.14.2 Boya Bio-Pharmaceutical Business Overview
  82. 7.14.3 Boya Bio-Pharmaceutical Blood Product Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Boya Bio-Pharmaceutical Blood Product Product Portfolio
  84. 7.14.5 Boya Bio-Pharmaceutical Recent Developments
  85. 7.15 Paisi Feike Biology Pharmacy Co., Ltd.
  86. 7.15.1 Paisi Feike Biology Pharmacy Co., Ltd. Company Information
  87. 7.15.2 Paisi Feike Biology Pharmacy Co., Ltd. Business Overview
  88. 7.15.3 Paisi Feike Biology Pharmacy Co., Ltd. Blood Product Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Paisi Feike Biology Pharmacy Co., Ltd. Blood Product Product Portfolio
  90. 7.15.5 Paisi Feike Biology Pharmacy Co., Ltd. Recent Developments
  91. 7.16 Xinjiang Deyuan Bioengineering
  92. 7.16.1 Xinjiang Deyuan Bioengineering Company Information
  93. 7.16.2 Xinjiang Deyuan Bioengineering Business Overview
  94. 7.16.3 Xinjiang Deyuan Bioengineering Blood Product Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Xinjiang Deyuan Bioengineering Blood Product Product Portfolio
  96. 7.16.5 Xinjiang Deyuan Bioengineering Recent Developments
  97. 7.17 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  98. 7.17.1 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Company Information
  99. 7.17.2 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Business Overview
  100. 7.17.3 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Blood Product Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Blood Product Product Portfolio
  102. 7.17.5 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Recent Developments
  103. 7.18 Shenzhen Weiguang
  104. 7.18.1 Shenzhen Weiguang Company Information
  105. 7.18.2 Shenzhen Weiguang Business Overview
  106. 7.18.3 Shenzhen Weiguang Blood Product Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Shenzhen Weiguang Blood Product Product Portfolio
  108. 7.18.5 Shenzhen Weiguang Recent Developments
  109. 7.19 Shanxi Kangbao
  110. 7.19.1 Shanxi Kangbao Company Information
  111. 7.19.2 Shanxi Kangbao Business Overview
  112. 7.19.3 Shanxi Kangbao Blood Product Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Shanxi Kangbao Blood Product Product Portfolio
  114. 7.19.5 Shanxi Kangbao Recent Developments
  115. 7.20 Nanyue Biopharming Corporation Ltd
  116. 7.20.1 Nanyue Biopharming Corporation Ltd Company Information
  117. 7.20.2 Nanyue Biopharming Corporation Ltd Business Overview
  118. 7.20.3 Nanyue Biopharming Corporation Ltd Blood Product Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Nanyue Biopharming Corporation Ltd Blood Product Product Portfolio
  120. 7.20.5 Nanyue Biopharming Corporation Ltd Recent Developments
8 North America
  1. 8.1 North America Blood Product Revenue (2021-2032)
  2. 8.2 North America Blood Product Revenue by Type (2021-2032)
  3. 8.2.1 North America Blood Product Revenue by Type (2021-2026)
  4. 8.2.2 North America Blood Product Revenue by Type (2027-2032)
  5. 8.3 North America Blood Product Revenue Share by Type (2021-2032)
  6. 8.4 North America Blood Product Revenue by Application (2021-2032)
  7. 8.4.1 North America Blood Product Revenue by Application (2021-2026)
  8. 8.4.2 North America Blood Product Revenue by Application (2027-2032)
  9. 8.5 North America Blood Product Revenue Share by Application (2021-2032)
  10. 8.6 North America Blood Product Revenue by Country
  11. 8.6.1 North America Blood Product Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Blood Product Revenue by Country (2021-2026)
  13. 8.6.3 North America Blood Product Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Blood Product Revenue (2021-2032)
  2. 9.2 Europe Blood Product Revenue by Type (2021-2032)
  3. 9.2.1 Europe Blood Product Revenue by Type (2021-2026)
  4. 9.2.2 Europe Blood Product Revenue by Type (2027-2032)
  5. 9.3 Europe Blood Product Revenue Share by Type (2021-2032)
  6. 9.4 Europe Blood Product Revenue by Application (2021-2032)
  7. 9.4.1 Europe Blood Product Revenue by Application (2021-2026)
  8. 9.4.2 Europe Blood Product Revenue by Application (2027-2032)
  9. 9.5 Europe Blood Product Revenue Share by Application (2021-2032)
  10. 9.6 Europe Blood Product Revenue by Country
  11. 9.6.1 Europe Blood Product Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Blood Product Revenue by Country (2021-2026)
  13. 9.6.3 Europe Blood Product Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Blood Product Revenue (2021-2032)
  2. 10.2 China Blood Product Revenue by Type (2021-2032)
  3. 10.2.1 China Blood Product Revenue by Type (2021-2026)
  4. 10.2.2 China Blood Product Revenue by Type (2027-2032)
  5. 10.3 China Blood Product Revenue Share by Type (2021-2032)
  6. 10.4 China Blood Product Revenue by Application (2021-2032)
  7. 10.4.1 China Blood Product Revenue by Application (2021-2026)
  8. 10.4.2 China Blood Product Revenue by Application (2027-2032)
  9. 10.5 China Blood Product Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Blood Product Revenue (2021-2032)
  2. 11.2 Asia Blood Product Revenue by Type (2021-2032)
  3. 11.2.1 Asia Blood Product Revenue by Type (2021-2026)
  4. 11.2.2 Asia Blood Product Revenue by Type (2027-2032)
  5. 11.3 Asia Blood Product Revenue Share by Type (2021-2032)
  6. 11.4 Asia Blood Product Revenue by Application (2021-2032)
  7. 11.4.1 Asia Blood Product Revenue by Application (2021-2026)
  8. 11.4.2 Asia Blood Product Revenue by Application (2027-2032)
  9. 11.5 Asia Blood Product Revenue Share by Application (2021-2032)
  10. 11.6 Asia Blood Product Revenue by Country
  11. 11.6.1 Asia Blood Product Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Blood Product Revenue by Country (2021-2026)
  13. 11.6.3 Asia Blood Product Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Blood Product Revenue (2021-2032)
  2. 12.2 SAMEA Blood Product Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Blood Product Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Blood Product Revenue by Type (2027-2032)
  5. 12.3 SAMEA Blood Product Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Blood Product Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Blood Product Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Blood Product Revenue by Application (2027-2032)
  9. 12.5 SAMEA Blood Product Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Blood Product Revenue by Country
  11. 12.6.1 SAMEA Blood Product Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Blood Product Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Blood Product Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst